Rtz LH, Sargent D, et al. New response evaluation criteria in solid tumours: 15857111 revised RECIST guideline. European journal of cancer 45: 228247. 33. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844847. 34. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with higher proliferation and poor patient survival. Am J Obstet Gynecol 199: 543 e541547. 35. Salvesen HB, Das S, Akslen LA Loss of nuclear p16 protein expression just isn’t associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6: 153159. 36. Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, et al. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with higher versus low HER-2/neu expression in vitro. Gynecol Oncol 119: 140145. 37. Hiramatsu HP, Kikuchi Y, Seto H, Nagata I In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan in mixture with other aniticancer drugs. Anticancer Drugs 11: 573578. 38. Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, et al. Evolution in endometrial cancer: evidence from an immunohistochemical study. Int J Gynecol Cancer 21: 316322. 39. Amant F, Mirza MR, Creutzberg CL Cancer of the corpus uteri. Int J Gynaecol Obstet 119 Suppl two: S110117. 40. Halle MK, Werner HM, Krakstad C, Birkeland E, Wik E, et al. Stratification based on higher tumour cell content in fresh frozen tissue promotes collection of aggressive endometrial carcinomas. Histopathology 60: 516519. 41. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, et al. Cell death modalities: classification and pathophysiological implications. Cell death and differentiation 14: 12371243. eight Stathmin Predicts Response in Endometrial Cancer 42. Taatjes DJ, Sobel BE, Budd RC Morphological and cytochemical determination of cell death by apoptosis. Histochemistry and cell biology 129: 3343. 43. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. Reporting suggestions for tumor marker prognostic studies. Journal of your National Cancer Institute 97: 11801184. 44. Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, et al. Insights in to the mechanism of microtubule stabilization by Taxol. Proceedings of your National Academy of Sciences of your United states of America 103: 1016610173. 45. Arslan C, Sari E, Aksoy S, Altundag K Variation in MedChemExpress I-BRD9 hormone receptor and HER-2 status involving main and metastatic breast cancer: critique on the literature. Expert opinion on therapeutic targets 15: 2130. 46. Khasraw M, Brogi E, Seidman AD The need to examine metastatic tissue in the time of Licochalcone A web progression of breast cancer: is re-biopsy a necessity or perhaps a luxury Current oncology reports 13: 1725. 47. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, et al. Does confirmatory tumor biopsy alter the management of breast cancer sufferers with 48. 49. 50. 51. 52. distant metastases Annals of oncology: official journal from the European Society for Healthcare Oncology/ESMO 20: 14991504. Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, et al. Loss of GPER identifies new targets for therapy among a subgroup of ERalpha-positive endometrial cancer patients with poor outcome. British journal of cancer 106: 16821688. Bi.Rtz LH, Sargent D, et al. New response evaluation criteria in solid tumours: 15857111 revised RECIST guideline. European journal of cancer 45: 228247. 33. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844847. 34. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 199: 543 e541547. 35. Salvesen HB, Das S, Akslen LA Loss of nuclear p16 protein expression isn’t related with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6: 153159. 36. Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, et al. Larger sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with higher versus low HER-2/neu expression in vitro. Gynecol Oncol 119: 140145. 37. Hiramatsu HP, Kikuchi Y, Seto H, Nagata I In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan in mixture with other aniticancer drugs. Anticancer Drugs 11: 573578. 38. Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, et al. Evolution in endometrial cancer: proof from an immunohistochemical study. Int J Gynecol Cancer 21: 316322. 39. Amant F, Mirza MR, Creutzberg CL Cancer from the corpus uteri. Int J Gynaecol Obstet 119 Suppl 2: S110117. 40. Halle MK, Werner HM, Krakstad C, Birkeland E, Wik E, et al. Stratification according to high tumour cell content material in fresh frozen tissue promotes collection of aggressive endometrial carcinomas. Histopathology 60: 516519. 41. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, et al. Cell death modalities: classification and pathophysiological implications. Cell death and differentiation 14: 12371243. eight Stathmin Predicts Response in Endometrial Cancer 42. Taatjes DJ, Sobel BE, Budd RC Morphological and cytochemical determination of cell death by apoptosis. Histochemistry and cell biology 129: 3343. 43. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. Reporting suggestions for tumor marker prognostic studies. Journal from the National Cancer Institute 97: 11801184. 44. Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, et al. Insights in to the mechanism of microtubule stabilization by Taxol. Proceedings of the National Academy of Sciences from the United states of america of America 103: 1016610173. 45. Arslan C, Sari E, Aksoy S, Altundag K Variation in hormone receptor and HER-2 status amongst primary and metastatic breast cancer: evaluation of the literature. Specialist opinion on therapeutic targets 15: 2130. 46. Khasraw M, Brogi E, Seidman AD The must examine metastatic tissue in the time of progression of breast cancer: is re-biopsy a necessity or possibly a luxury Present oncology reports 13: 1725. 47. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, et al. Does confirmatory tumor biopsy alter the management of breast cancer sufferers with 48. 49. 50. 51. 52. distant metastases Annals of oncology: official journal from the European Society for Medical Oncology/ESMO 20: 14991504. Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, et al. Loss of GPER identifies new targets for therapy among a subgroup of ERalpha-positive endometrial cancer individuals with poor outcome. British journal of cancer 106: 16821688. Bi.